Evaluating the Association between Artificial Light-at-Night Exposure and Breast and Prostate Cancer Risk in Spain (MCC-Spain Study).

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read Online Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: National Institute of Environmental Health Sciences Country of Publication: United States NLM ID: 0330411 Publication Model: Electronic Cited Medium: Internet ISSN: 1552-9924 (Electronic) Linking ISSN: 00916765 NLM ISO Abbreviation: Environ Health Perspect Subsets: MEDLINE
    • Publication Information:
      Original Publication: Research Triangle Park, N. C. National Institute of Environmental Health Sciences.
    • Subject Terms:
      Breast Neoplasms/*epidemiology ; Light/*adverse effects ; Lighting/*adverse effects ; Prostatic Neoplasms/*epidemiology; Adult ; Aged ; Aged, 80 and over ; Breast Neoplasms/etiology ; Case-Control Studies ; Circadian Rhythm ; Female ; Humans ; Incidence ; Male ; Middle Aged ; Prostatic Neoplasms/etiology ; Risk Factors ; Spain/epidemiology ; Young Adult
    • Abstract:
      Background: Night shift work, exposure to light at night (ALAN) and circadian disruption may increase the risk of hormone-dependent cancers.
      Objectives: We evaluated the association of exposure to ALAN during sleeping time with breast and prostate cancer in a population based multicase-control study (MCC-Spain), among subjects who had never worked at night. We evaluated chronotype, a characteristic that may relate to adaptation to light at night.
      Methods: We enrolled 1,219 breast cancer cases, 1,385 female controls, 623 prostate cancer cases, and 879 male controls from 11 Spanish regions in 2008-2013. Indoor ALAN information was obtained through questionnaires. Outdoor ALAN was analyzed using images from the International Space Station (ISS) available for Barcelona and Madrid for 2012-2013, including data of remotely sensed upward light intensity and blue light spectrum information for each geocoded longest residence of each MCC-Spain subject.
      Results: Among Barcelona and Madrid participants with information on both indoor and outdoor ALAN, exposure to outdoor ALAN in the blue light spectrum was associated with breast cancer [adjusted odds ratio (OR) for highest vs. lowest tertile, OR=1.47; 95% CI: 1.00, 2.17] and prostate cancer (OR=2.05; 95% CI: 1.38, 3.03). In contrast, those exposed to the highest versus lowest intensity of outdoor ALAN were more likely to be controls than cases, particularly for prostate cancer. Compared with those who reported sleeping in total darkness, men who slept in "quite illuminated" bedrooms had a higher risk of prostate cancer (OR=2.79; 95% CI: 1.55, 5.04), whereas women had a slightly lower risk of breast cancer (OR=0.77; 95% CI: 0.39, 1.51).
      Conclusion: Both prostate and breast cancer were associated with high estimated exposure to outdoor ALAN in the blue-enriched light spectrum. https://doi.org/10.1289/EHP1837.
    • References:
      Int J Cancer. 2015 Sep 1;137(5):1147-57. (PMID: 25530021)
      Epidemiology. 2014 Sep;25(5):697-706. (PMID: 25061924)
      Eur J Epidemiol. 2016 Sep;31(9):867-78. (PMID: 26205167)
      Environ Health Perspect. 2017 Aug 17;125(8):087010. (PMID: 28886600)
      J Clin Endocrinol Metab. 2005 Mar;90(3):1311-6. (PMID: 15585546)
      Sci Rep. 2014 Jan 21;4:3789. (PMID: 24445659)
      Proc Natl Acad Sci U S A. 2015 Jan 27;112(4):1232-7. (PMID: 25535358)
      Philos Trans R Soc Lond B Biol Sci. 2015 May 5;370(1667):null. (PMID: 25780233)
      Curr Biol. 2016 May 23;26(10):R432-43. (PMID: 27218855)
      Scand J Work Environ Health. 2017 Nov 1;43(6):560-568. (PMID: 28879368)
      Philos Trans R Soc Lond B Biol Sci. 2015 May 5;370(1667):null. (PMID: 25780244)
      J Pineal Res. 2008 Jan;44(1):41-4. (PMID: 18078446)
      Int J Mol Sci. 2014 Dec 17;15(12):23448-500. (PMID: 25526564)
      Front Public Health. 2015 Oct 13;3:233. (PMID: 26528465)
      Chronobiol Int. 2011 Feb;28(1):76-80. (PMID: 21182407)
      Cancer Epidemiol Biomarkers Prev. 2014 Jul;23(7):1176-86. (PMID: 24812038)
      Chronobiol Int. 2011 Oct;28(8):673-80. (PMID: 21867367)
      Chronobiol Int. 2015;32(6):757-73. (PMID: 26102518)
      Cancer Causes Control. 2010 Dec;21(12):2059-68. (PMID: 20680434)
      Gac Sanit. 2015 Jul-Aug;29(4):308-15. (PMID: 25613680)
      J Physiol. 2001 Aug 15;535(Pt 1):261-7. (PMID: 11507175)
      Philos Trans R Soc Lond B Biol Sci. 2015 May 5;370(1667):null. (PMID: 25780231)
      J Environ Manage. 2011 Oct;92(10):2714-22. (PMID: 21745709)
      Sci Adv. 2016 Jun 10;2(6):e1600377. (PMID: 27386582)
      Occup Environ Med. 2017 Mar;74(3):159-160. (PMID: 27852644)
      Sci Adv. 2017 Nov 22;3(11):e1701528. (PMID: 29181445)
      Chronobiol Int. 2009 Jan;26(1):108-25. (PMID: 19142761)
      Chronobiol Int. 2016;33(8):943-5. (PMID: 27254140)
      Integr Cancer Ther. 2016 Jun;15(2):145-52. (PMID: 26631258)
      J Neurosci. 2001 Aug 15;21(16):6405-12. (PMID: 11487664)
      PLoS Genet. 2016 Aug 05;12(8):e1006125. (PMID: 27494321)
      Chronobiol Int. 2017;34(8):1125-1135. (PMID: 28759270)
      Int J Health Geogr. 2013 Apr 17;12:23. (PMID: 23594790)
      PLoS One. 2013 Jul 05;8(7):e67798. (PMID: 23861808)
      Integr Cancer Ther. 2017 Dec;16(4):451-463. (PMID: 27899698)
      Cancer Epidemiol Biomarkers Prev. 2015 May;24(5):854-63. (PMID: 25737330)
      Endocr Relat Cancer. 2015 Jun;22(3):R183-204. (PMID: 25876649)
      Int J Obes (Lond). 2016 May;40(5):815-23. (PMID: 26795746)
    • Publication Date:
      Date Created: 20180425 Date Completed: 20190201 Latest Revision: 20190201
    • Publication Date:
      20231215
    • Accession Number:
      PMC6071739
    • Accession Number:
      10.1289/EHP1837
    • Accession Number:
      29687979